A drug candidate developed by Senior Staff Scientist Pamela Maher and first author Gamze Ates of the Schubert lab, and previously shown to slow aging in brain cells, successfully reversed memory loss in a mouse model of inherited Alzheimer’s disease. The new research also revealed that the drug, CMS121, works by changing how brain cells metabolize fatty molecules known as lipids.
Read News ReleaseProfessor and VP/CSO Martin Hetzer, co-first authors Simone Bersini and Roberta Schulte, and colleagues have used skin cells called fibroblasts from young and old patients to successfully create blood vessel cells that retain their molecular markers of age. The team’s approach revealed clues as to why blood vessels tend to become leaky and hardened with age, and lets researchers identify new molecular targets to potentially slow aging in vascular cells.
Read News Release
Leading Salk science into the futureInside Salk sat down with Rusty Gage to learn more about his background, approach to managing a world-renowned Institute, and vision for Salk science over the next decade.
Julie Law – Revealing RNAAssociate Professor Julie Law shares common themes underlying her research and discusses what motivates her both in and out of the lab.
Gerald Pao – Pushing the limits in science and lifeFrom studying the novel coronavirus to downloading brains to computers, Staff Scientist Gerald Pao is at the forefront of scientific advancement.
Austin ColeyAustin Coley, though only at Salk since 2019, has already taken an active role in everything from conducting innovative research on the brain to spearheading a wide variety of outreach activities.
Salk’s Harnessing Plants Initiative (HPI) Garners Widespread SupportNew grants are supporting the Institute’s efforts to optimize plants’ natural ability to store carbon and mitigate climate change. This support bolsters the ongoing HPI project focused on model plants that was funded through donations to The Audacious Project in 2019.
